[Abstract] High-content screening is a useful tool to understand complex cellular processes and to identify genes, proteins or small molecule compounds that modulate such pathways. High-content assays monitor the function of a protein or pathway by visualizing a change in an image-based readout, such as a change in the localization of a reporter protein. Examples of this can be the translocation of a fluorescently tagged protein from the cytoplasm to the nucleus or to the plasma membrane. One protein that is known to undergo such translocation is the Growth Factor Receptor-bound protein 2 (GRB2) that is recruited to the plasma membrane upon stimulation of a growth factor receptor and subsequently undergoes internalization. We have used GFP-tagged Grb2 previously to identify genes that are involved in EGFR signaling (Petschnigg et al., 2017) . Ultimately, the assay can be adapted to cDNA expression cloning (Freeman et al., 2012) and can be used in early stage drug discovery to identify compounds that modulate or inhibit EGFR signaling and internalization (Antczak and Djaballah, 2016) .
[Background] Signal transduction by growth factor receptors is essential for cells to maintain proper function and thus requires tight control. Signal transduction by growth factor receptors is initiated by binding of an external ligand (e.g., Epidermal Growth Factor, EGF) to a transmembrane receptor such as the Epidermal Growth Factor Receptor (EGFR) and activation of downstream signaling cascades (Yao et al., 2015) . A key regulator of EGFR-signaling is Growth Factor Receptor-bound protein 2 (Grb2), which is composed of an internal SH2 (Src homology 2) domain flanked by two SH3 domains. Grb2 binds to activated growth factor receptors at phosphorylated tyrosine residues through its SH2 domain, thus coupling receptor activation to SOS-Ras-MAPK (Mitogen-activated protein kinase) signaling cascades. The composition of Grb2 suggests that it can dock to a variety of receptors and transduce signals along multiple pathways. Mutations in signaling pathways frequently lead to the development of cancer. Hence, in order to better understand how aberrant signaling can lead to disease, it is important to identify novel signaling molecules in growth factor signaling. To accomplish this, we used the previously established microscopy-based GFP-Grb2 translocation assay that monitors the translocation of cytosolic GFP-tagged Grb2 to subcellular compartments upon expression of a cDNA library ( Figure   1 ). We used this technique to identify novel proteins that can lead to translocation of GFP-Grb2 when overexpressed and in a second stage tested whether these proteins play a role in EGFR-signaling (Petschnigg et al., 2017) . Examples that lead to punctate structures include TACC3, a novel EGFRinteractor, and AMPH ( Figure 3 ). TACC3 led to induction of large GFP-Grb2 puncta, whereas AMPH www.bio-protocol.org/e2528 results in formation of multiple small spots (Figure 3 ), pointing at potentially different mechanisms of those proteins in EGFR-signaling. In our recent study, we further characterized TACC3 and showed that TACC3 specifically binds to oncogenic EGFR variants and showed that TACC3 enhances EGFRstability at the cell surface and increases EGFR-mediated signaling. The GFP-Grb2 assay can be expanded to multiple more applications. A siRNA/shRNA or CRISPR library could be co-expressed with GFP-Grb2 and translocation subsequently observed following EGF stimulation. As EGF stimulation would sequester GFP-Grb2 to endosomal structures and the plasma membrane, translocation from there upon siRNA/shRNA knockdown or CRISPR knockout could point at possible factors that ablate EGFR-Grb2 interactions and signaling. In a similar way, small molecule compound screens could be done to test for drugs that can specifically disrupt EGFR-Grb2 interactions upon EGF-stimulation ( Figure   1 ). Other options could be to use mutated Grb2-variants that fail to bind to EGFR or other binding partners, thus the assay can give insight into which gene (when overexpressed or knock-downed) or which drug has an influence on specific binding domains of Grb2. www.bio-protocol.org/e2528 6. Add PEI (10 mg/ml solution) at a ratio of 4:1, i.e., for 200 ng total DNA add 0.8 µl PEI.
7. Vortex the DMEM/DNA/PEI-mix and leave at room temperature for 15-20 min.
8. Add the DMEM/DNA/PEI-mix dropwise to cells using a gentle dispensing method.
Note: Alternatively, the transfection mix can be dispensed first into plates and then cells added on top (reverse transfection).
9. 6 h after transfection, replace the transfection mix with fresh DMEM plus FBS/penicillinstreptomycin media.
10. Incubate cells overnight at 37 °C and 5% CO2.
11. The next day, aspirate off the media and wash the cells once with 1x PBS (see Recipes).
Note: At this stage, treatments such as EGF stimulation or drug treatment can be performed before the PBS-wash, depending on the duration of the incubation (e.g., 10 min EGF, or a couple of hours of drugs).
12. Add 50 µl of 4% PFA in PBS to each well and incubate for 10 min at room temperature. 13. Aspirate off the PFA and wash once with 1x PBS.
14. Add Hoechst 33342 (diluted 1:10,000 in 1x PBS) for 10 min.
www.bio-protocol.org/e2528 16. Acquire images on a suitable fluorescence microscope (e.g., Opera Phenix) with the following settings: Channel 488 nm for GFP, 100% laser power, 40x objective, binning '1', exposure time may vary between 500 msec and 2 sec, depending on transfection efficiency and brightness. Figure 2 shows the settings on the Opera-high-content screening microscope. Example images (TACC3-overexpression and AMPH-overexpression compared to GFP-Grb2 only) are shown in Figure 3 .
17. Perform image analysis or qualitatively assess images by eye. Other instruments vary in the layout and setup of settings.
